Caplin Point Laboratories' Q3 FY 2025-26 Quarterly Results
- 06 Feb 2026
Result Summary
- Caplin Point Laboratories Ltd reported a 2.1% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 9.9%.
- Its expenses for the quarter were up by 2.5% QoQ and 7.3% YoY.
- The net profit increased 3.5% QoQ and increased 18.4% YoY.
- The earnings per share (EPS) of Caplin Point Laboratories Ltd stood at 21.51 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 576.45 | 564.41 | 524.32 | 2.1% | 9.9% |
Total Expenses | 372.54 | 363.43 | 347.05 | 2.5% | 7.3% |
Profit Before Tax | 203.91 | 200.98 | 177.27 | 1.5% | 15.0% |
Tax | 38.03 | 40.77 | 37.19 | -6.7% | 2.3% |
Profit After Tax | 165.86 | 160.23 | 140.07 | 3.5% | 18.4% |
Earnings Per Share | 21.51 | 20.25 | 18.19 | 6.2% | 18.3% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Caplin Point Laboratories Ltd is a pharmaceutical company primarily engaged in the development, manufacturing, and marketing of a broad range of generic formulations and branded products. The company caters to markets in Latin America, Africa, and the United States, offering products across various therapeutic segments, including anti-infectives, analgesics, and anti-inflammatory medications. Caplin Point Laboratories is known for its focus on emerging markets and has been expanding its product portfolio and market presence over recent years. As of the latest updates, the company has been working on increasing its footprint in the U.S. and other regulated markets through strategic partnerships and product launches.
Revenue
In the third quarter of fiscal year 2026 (Q3FY26), Caplin Point Laboratories Ltd reported a total income of ₹576.45 crores. This represents a quarter-over-quarter (QoQ) increase of 2.1% from ₹564.41 crores in the second quarter of fiscal year 2026 (Q2FY26). Furthermore, there was a year-over-year (YoY) growth of 9.9% compared to ₹524.32 crores in the third quarter of fiscal year 2025 (Q3FY25). These figures suggest a consistent growth pattern in the company's revenue over the period analyzed.
Profitability
The company's profit before tax for Q3FY26 was ₹203.91 crores, reflecting a QoQ increase of 1.5% from ₹200.98 crores in Q2FY26. Compared to the same quarter in the previous fiscal year, there was a YoY growth of 15.0% from ₹177.27 crores. The tax expense for Q3FY26 was ₹38.03 crores, which was a decrease of 6.7% QoQ from Q2FY26 and a slight increase of 2.3% YoY. Consequently, the profit after tax for the quarter was ₹165.86 crores, marking a 3.5% QoQ increase and an 18.4% YoY rise. The earnings per share (EPS) for Q3FY26 was ₹21.51, up 6.2% from the previous quarter and 18.3% from the same quarter last year.
Operating Metrics
Total expenses for Caplin Point Laboratories in Q3FY26 amounted to ₹372.54 crores, which is a 2.5% increase from ₹363.43 crores in Q2FY26. On a year-over-year basis, total expenses rose by 7.3% from ₹347.05 crores in Q3FY25. Despite the increase in expenses, the company managed to maintain a positive trajectory in its profitability metrics, as evidenced by the increase in profit after tax and earnings per share. This performance indicates efficient expense management and operational effectiveness in sustaining growth despite rising costs.